knowledge -WSS

knowledge

author：knowledge 2025-09-29 01:37:35 - browse：39

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： STAT Summit: GSK CEO on pharma giant's new direction

WSS

STAT Summit: Biotech founders on deal

Why health workers in Gaza are injured or die at high rates

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

The U.S. needs a new definition of substance use “recovery”

Pandemic and All Hazards Preparedness Act needs lean update

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biden’s NIH nominee is languishing in Congress

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Studies point to risks of excluding people with obesity from drug trials

Jerome Adams on the need for new antivirals for Covid

Eli Lilly expects to double planned employment in Boston center

Wikipedia

The EU Joint Clinical Assessment needs to live up to its promise

STAT Summit: How a Chicago ER doctor tackles gun violence

Eli Lilly expects to double planned employment in Boston center

Swim instructor mom warns parents not to buy blue swimsuits for kids

CEOs share strategies for surviving biotech slump

White House announces new plan to address the growing threat of xylazine in overdose crisis

focus

entertainment

knowledge

hotspot